Could a Low-Protein diet boost immunotherapy for melanoma?

NCT ID NCT07586891

Recruiting now Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a low branched-chain amino acid (BCAA) diet, when combined with an immunotherapy drug (anti-PD-1), is safe and effective for people with stage III melanoma. About 80 participants will receive either the special diet or a normal diet alongside the immunotherapy. The goal is to see if the diet helps the immune system fight the cancer better, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low branched-chain amino acid diet and anti-PD-1 monoclonal antibody
What this could lead to: If successful, this combination could improve how well immunotherapy works for stage III melanoma, potentially leading to better tumor shrinkage and longer survival.
What could go wrong: This is a small, early exploratory study with only 80 participants. The diet may not add benefit over standard immunotherapy, and side effects from the combination are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (SKIN CANCER)

Contacts and locations

Locations

Xijing Hospital, Air Force Medical University
RECRUITING

Xi'an, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.